UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: February 17, 2019 (Date of earliest event reported) |
REVA MEDICAL, INC. |
(Exact name of registrant as specified in its charter)
|
Delaware | 000-54192 | 33-0810505 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
5751 Copley Drive, San Diego, CA | 92111 |
(Address of principal executive offices) | (Zip Code) |
(858) 966-3000 |
(Registrant’s telephone number, including area code) |
|
|
(Former Name or Former Address, if changed since last report) |
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
|
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Item 8.01 Other Events
On February 18, 2019 AEDT, the Australian Securities Exchange issued a market announcement indicating that the securities of Reva Medical, Inc. (“Reva” or the “Company”) have been placed in a trading halt at our request through the end of trading on February 19, 2019. The request for trading halt was made in accordance with ASX Listing Rule 17.1 while the Company engages in discussions with representatives of certain of its major debt and equity holders to attempt to address the Company’s immediate financing needs.
On February 17, 2019 PST, the Company issued a press release announcing the changes described above, which press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit Number |
| Description |
99.1 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| REVA Medical, Inc. |
|
|
|
|
Date: February 17, 2019 | /s/ Leigh F. Elkolli |
| Leigh F. Elkolli |
| Chief Financial Officer and Corporate Secretary |
|
|
|
|
|
|